Assessing response to anti-CD20 therapy by genotyping C1q components
View Patent ↗The present invention encompasses methods for predicting metastasis in cancer by assessing the structure of the complement protein C1qA. The methods may encompass examining either protein or nucleic acids, and may further include making treatment decisions based on the predictive methods.
1. A method for determine an increased likelihood that a human subject will have a prolonged response period to treatment of follicular lymphoma with Rituximab monoclonal antibody therapy, said method comprising:
(a) obtaining a sample from said subject, said sample comprising nucleic acids from the subject;
(b) detecting in said nucleic acids the presence of at least one allele of the ClqA gene comprising an A nucleotide at the position corresponding to position 276 of SEQ ID NO:6; and
(c) correlating the presence of said A nucleotide with an increased likelihood that the subject will have a prolonged response period to treatment of follicular lymphoma with Rituximab monoclonal antibody therapy.
2. The method of claim 1 , wherein detecting comprises sequencing, primer extension, differential hybridization, RFLP analysis, SNP analysis, molecular beacon analysis, and mass spectrometry.
3. The method of claim 2 , wherein detecting comprises PCR-based sequencing.
4. The method of claim 1 , further comprising obtaining genomic DNA from said subject.
5. The method of claim 1 , wherein said patient has not been previously diagnosed with cancer.
6. The method of claim 1 , wherein said patient has been previously diagnosed with cancer.
7. The method of claim 1 , wherein said patient has previously been treated with an anti-CD20 antibody.
8. The method of claim 1 , wherein said patient has not been treated with an anti-CD20 antibody.
9. The method of claim 1 , further comprising making a treatment decision based on step (c).
10. The method of claim 1 , further comprising treating said patient.
11. The method of claim 10 , wherein treating comprises treating with Rituximab monoclonal antibody therapy.
12. The method of claim 10 , wherein treating comprises surgery, chemotherapy, radiotherapy, hormonal therapy, immunotherapy other than rituximab, cytokine therapy or gene therapy.